Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 11/20 | 0.50 |
| ▸ | RAF1 | P04049 | 7/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | STK4 | Q13043 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27638824 | 0.89 | MAP2K1 (0.67) | SRCMAP2K1RAF1 | |
| SCHEMBL676613 | 0.77 | MAP2K1 (0.78) | MAP2K1RAF1EGFRERBB2STK4 | |
| SCHEMBL29556194 | 0.77 | MAP2K1 (0.78) | MAP2K1RAF1EGFRERBB2STK4 | |
| SCHEMBL4899266 | 0.75 | SRC (0.68) | SRC | |
| SCHEMBL13399957 | 0.74 | AURKA (0.50) | KDRRAB9A | |
| SCHEMBL15655816 | 0.73 | GSK3B (0.48) | HCRTR1MAPTALOX15TSHRMAPK1 | |
| SCHEMBL868127 | 0.72 | MAP2K1 (0.60) | SRCMAP2K1RAF1EGFRERBB2 | |
| SCHEMBL5011206 | 0.72 | MAP2K1 (0.67) | SRCMAP2K1RAF1EGFRERBB2 | |
| SCHEMBL14369942 | 0.71 | SRC (0.46) | SRCEGFRERBB2TSHRRAB9A | |
| SCHEMBL3355756 | 0.71 | SRC (0.49) | SRCKDRALOX15LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | SRC 2427/4885MAP2K1 1782/4885RAF1 1737/4885 |
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | SRC 2694/4885MAP2K1 2215/4885RAF1 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.